{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:24:54Z","timestamp":1787955894880,"version":"build-2784847793"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-\u03b22 glycoprotein I domain 1 (anti-\u03b22GPI-D1) antibodies have shown promise as diagnostic and prognostic markers for antiphospholipid syndrome (APS), but their clinical significance remains uncertain. This systematic review and meta-analysis evaluated the diagnostic accuracy of anti-\u03b22GPI-D1 for APS and its association with thrombotic risk. A comprehensive search was conducted across PubMed, Web of Science, and Embase up to July 18, 2024. Eighteen studies (2,060 APS patients and 3,013 controls) were included in the diagnostic analysis, revealing a pooled sensitivity of 52% (95% CI 46%-58%) and specificity of 95% (95% CI 88%-98%). Anti-\u03b22GPI-D1 demonstrated strong diagnostic value in distinguishing APS from other autoimmune diseases and healthy individuals, though its utility in differentiating APS from aPL carriers was limited. Additionally, five prospective cohort studies (210 APS patients, 430 aPL carriers, and 42 SLE patients) showed that anti-\u03b22GPI-D1 was associated with an increased risk of thrombosis (pooled RR 1.75, 95% CI 1.07-2.87). Our findings suggest that anti-\u03b22GPI-D1 offers high specificity and moderate sensitivity for APS diagnosis and may serve as a predictor of thrombosis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1541165","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:37:48Z","timestamp":1745393868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-\u03b22 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Linhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.v75.10","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000070","article-title":"Immunoglobulin G is the only anti-beta-2-glycoprotein I isotype that associates with unprovoked thrombotic events among hospital patients","volume":"46","author":"Brusch","year":"2014","journal-title":"Pathology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005205","article-title":"A systematic review of the association between anti-\u03b2-2 glycoprotein I antibodies and APS manifestations","volume":"5","author":"Jiang","year":"2021","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1601329","article-title":"The significance of antibodies against domain I of beta-2 glycoprotein I in antiphospholipid syndrome","volume":"44","author":"Kelchtermans","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.006","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome","volume":"12","author":"Mahler","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025321617304","article-title":"Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome","volume":"23","author":"Shoenfeld","year":"2003","journal-title":"J Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu360","article-title":"Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of \u03b22-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis","volume":"54","author":"Pericleous","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to \u03b22 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: Anti-\u03b22GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.42459","article-title":"Fluctuation of anti\u2013domain 1 and anti\u2013\u03b22-glycoprotein I antibody titers over time in patients with persistently positive antiphospholipid antibodies","volume":"75","author":"Chighizola","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13389","article-title":"Role of anti-domain 1-\u03b22 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome","volume":"14","author":"De Craemer","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.11.029","article-title":"Anti-\u03b22GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome","volume":"185","author":"Liu","year":"2020","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23310","article-title":"First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: A combination of anti-\u03b2(2) -glycoprotein I domain I and anti-phosphatidylserine\/prothrombin complex antibodies tests","volume":"70","author":"Nakamura","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2016.08.018","article-title":"Significance of fully automated tests for the diagnosis of antiphospholipid syndrome","volume":"146","author":"Oku","year":"2016","journal-title":"Thromb Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.04.031","article-title":"Antibodies to Domain 4\/5 (Dm4\/5) of \u03b22-Glycoprotein 1 (\u03b22GP1) in different antiphospholipid (aPL) antibody profiles","volume":"136","author":"Pengo","year":"2015","journal-title":"Thromb Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04197.x","article-title":"Anti-\u03b22glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model","volume":"9","author":"Forastiero","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.03.019","article-title":"Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine\/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology","volume":"202","author":"Radin","year":"2021","journal-title":"Thromb Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02406-6","article-title":"Double positivity of anti-\u03b2(2)-glycoprotein I domain I and anti-phosphatidylserine\/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody","volume":"52","author":"Yun","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-0676","article-title":"Coexistence of anti-\u03b22-glycoprotein I domain I and anti-phosphatidylserine\/prothrombin antibodies suggests strong thrombotic risk","volume":"55","author":"Lee","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1002\/9781119756194.ch9","article-title":"Chapter 9: understanding meta-analysis","volume-title":"Cochrane handbook for systematic reviews of diagnostic test accuracy. Version 2.0 (updated july 2023)","author":"Macaskill","year":"2023"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640366","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome","volume":"25","author":"Mahler","year":"2016","journal-title":"Lupus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.04.033","article-title":"Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome","volume":"446","author":"Meneghel","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000924","article-title":"Anti-\u03b22GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China","volume":"10","author":"Zhou","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1134\/S1607672923700278","article-title":"Antibodies to domain I \u03b2(2)-glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus","volume":"511","author":"Reshetnyak","year":"2023","journal-title":"Dokl Biochem Biophys"},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-020-2131-4","article-title":"Non-criteria\u201d antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz085","article-title":"Laboratory evaluation of antiphospholipid syndrome: is there a role for specific noncriteria antiphospholipid antibody tests","volume":"152","author":"Heikal","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02971","article-title":"Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria","volume":"9","author":"Litvinova","year":"2018","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.02.019","article-title":"Clinical significance of anti-domain 1 \u03b22-glycoprotein I antibodies in antiphospholipid syndrome","volume":"153","author":"Iwaniec","year":"2017","journal-title":"Thromb Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"23839","DOI":"10.1038\/srep23839","article-title":"Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0156407","DOI":"10.1371\/journal.pone.0156407","article-title":"Measuring igA anti-\u03b22-glycoprotein I and igG\/igA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome","volume":"11","author":"Pericleous","year":"2016","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.39187","article-title":"Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against \u03b22 -glycoprotein i domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome","volume":"67","author":"Andreoli","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfaa072","article-title":"Anti-domain I \u03b22-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T study","volume":"5","author":"Zuily","year":"2020","journal-title":"J Appl Lab Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320916527","article-title":"Global antiphospholipid syndrome score and anti-\u00df2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study","volume":"29","author":"Nascimento","year":"2020","journal-title":"Lupus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.06.037","article-title":"Clinical value of anti-domain I-\u03b22Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study","volume":"485","author":"Tonello","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0144-8","article-title":"Autoantibodies directed against domain I of beta2-glycoprotein I","volume":"13","author":"de Laat","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead303","article-title":"Profile and clinical relevance of non-criteria antiphospholipid antibodies in patients diagnosed with or highly suspected of APS","volume":"63","author":"Li","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221945","article-title":"Seronegative antiphospholipid syndrome: refining the value of \u201cnon-criteria\u201d antibodies for diagnosis and clinical management","volume":"105","author":"Pignatelli","year":"2020","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies","volume":"169","author":"Iverson","year":"2002","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of \u03b22-glycoprotein and their presence correlates strongly with thrombosis","volume":"105","author":"De Laat","year":"2005","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"Si64","DOI":"10.1093\/rheumatology\/kead632","article-title":"Viewpoint: The value of non-criteria antiphospholipid antibodies","volume":"63","author":"de Laat","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198119","article-title":"New insight into antiphospholipid syndrome: antibodies to \u03b22glycoprotein I-domain 5 fail to induce thrombi in rats","volume":"104","author":"Durigutto","year":"2019","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14682","article-title":"Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study","volume":"18","author":"Yin","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206483","article-title":"Antibodies to domain I of \u03b2-2-glycoprotein I and IgA antiphospholipid antibodies in patients with \u2018seronegative\u2019 antiphospholipid syndrome","volume":"74","author":"Cousins","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-\u03b22 glycoprotein I domain I antibodies: A systematic review","volume":"44","author":"Radin","year":"2018","journal-title":"Semin Thromb Hemost"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1541165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:37:50Z","timestamp":1745393870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1541165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2025.1541165"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1541165","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"article-number":"1541165"}}